Circulation of influenza A viruses among patients hospitalized for severe acute respiratory infection in a tertiary care hospital in Romania in the 2018/19 season

Results from an observational descriptive epidemiological study

Anca Cristina Drăgănescu, MD, PhD,a, Victor Daniel Miron, MD, PhD,b,c, Anca Streinu-Cercel, MD, PhD,a,b, Dragoș Florea, MD, PhD,a,b, Ovidiu Vlaicu, PhD,b, Anuța Bilașco, MD,b, Dan Oțelea, MD, PhD,b, Monica Lumința Luminos, MD, PhD,a,b, Daniela Pățigoi, MD, PhD,a,b, Adrian Streinu-Cercel, MD, PhD,a,b, Oana Sândulescu, MD, PhD,a,b

Editor: Oliver Schüldgen.

The Global Influenza Hospital Surveillance Network (GIHSN) project was co-funded by the Foundation for Influenza Epidemiology and NIID. The Development of Robust and Innovative Vaccine Effectiveness (DRIVE) study has received support from the EU/EFPIA Innovative Medicines Initiative 2 Joint Undertaking (DRIVE, grant no. 777363) and was co-funded by NIID.

Anca Cristina Drăgănescu reports being manager of the GIHSN project co-funded by Foundation for Influenza Epidemiology and manager of the DRIVE study, that has received support from the EU/EFPIA Innovative Medicines Initiative 2 Joint Undertaking (DRIVE, grant no. 777363), within the scope of the submitted work.

Victor Daniel Miron reports being member of the research team of the GIHSN project co-funded by Foundation for Influenza Epidemiology and member of the research team of the DRIVE study, that has received support from the EU/EFPIA Innovative Medicines Initiative 2 Joint Undertaking (DRIVE, grant no. 777363), within the scope of the submitted work.

Anca Streinu-Cercel reports being member of the research team of the DRIVE study, that has received support from the EU/EFPIA Innovative Medicines Initiative 2 Joint Undertaking (DRIVE, grant no. 777363), within the scope of the submitted work.

Dragoș Florea reports being member of the research team of the GIHSN project co-funded by Foundation for Influenza Epidemiology, and member of the research team of the DRIVE study, that has received support from the EU/EFPIA Innovative Medicines Initiative 2 Joint Undertaking (DRIVE, grant no. 777363), within the scope of the submitted work.

Ovidiu Vlaicu reports being member of the research team of the GIHSN project co-funded by Foundation for Influenza Epidemiology and member of the research team of the DRIVE study, that has received support from the EU/EFPIA Innovative Medicines Initiative 2 Joint Undertaking (DRIVE, grant no. 777363), within the scope of the submitted work.

Anuța Bilașco reports being member of the research team of the GIHSN project co-funded by Foundation for Influenza Epidemiology and member of the research team of the DRIVE study, that has received support from the EU/EFPIA Innovative Medicines Initiative 2 Joint Undertaking (DRIVE, grant no. 777363), within the scope of the submitted work.

Dan Oțelea reports being member of the research team of the GIHSN project co-funded by Foundation for Influenza Epidemiology and member of the research team of the DRIVE study, that has received support from the EU/EFPIA Innovative Medicines Initiative 2 Joint Undertaking (DRIVE, grant no. 777363), within the scope of the submitted work.

Monica Lumința Luminos reports being member of the research team of the GIHSN project co-funded by Foundation for Influenza Epidemiology and member of the research team of the DRIVE study, that has received support from the EU/EFPIA Innovative Medicines Initiative 2 Joint Undertaking (DRIVE, grant no. 777363), within the scope of the submitted work.

Daniela Pățigoi reports being technical project manager of the GIHSN project co-funded by Foundation for Influenza Epidemiology and technical project manager of the DRIVE study, that has received support from the EU/EFPIA Innovative Medicines Initiative 2 Joint Undertaking (DRIVE, grant no. 777363), within the scope of the submitted work.

Adrian Streinu-Cercel reports being member of the research team of the GIHSN project co-funded by Foundation for Influenza Epidemiology and member of the research team of the DRIVE study, that has received support from the EU/EFPIA Innovative Medicines Initiative 2 Joint Undertaking (DRIVE, grant no. 777363), within the scope of the submitted work, and being principal investigator in influenza clinical trials by Shionogi and F. Hoffmann-La Roche, outside the scope of the submitted work.

Oana Sândulescu reports being member of the research team of the GIHSN project co-funded by Foundation for Influenza Epidemiology and principal investigator for adults in the DRIVE study, that has received support from the EU/EFPIA Innovative Medicines Initiative 2 Joint Undertaking (DRIVE, grant no. 777363), within the scope of the submitted work, and being subinvestigator in influenza clinical trials by Shionogi and F. Hoffmann-La Roche, outside the scope of the submitted work.

The authors report no conflicts of interest.

The datasets generated during and/or analyzed during the current study are available from the corresponding author on reasonable request.

© National Institute for Infectious Diseases “Prof. Dr. Matei Balș”, Bucharest, Romania, a Carol Davila University of Medicine and Pharmacy, Bucharest, Romania.

Correspondence: Victor Daniel Miron, Carol Davila University of Medicine and Pharmacy, 1 Doctor Calistrat Grozovici Street, Second District, 021105 Bucharest, Romania (e-mail: victor.miron@drd.umfcd.ro, mironvictordaniel@gmail.com).

Copyright © 2021 the Author(s). Published by Wolters Kluwer Health, Inc.

This is an open access article distributed under the Creative Commons Attribution License 4.0 (CCBY), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

How to cite this article: Drăgănescu AC, Miron VD, Streinu-Cercel A, Florea D, Vlaicu O, Bilașco A, Oțelea D, Luminos ML, Pățigoi D, Streinu-Cercel A, Sândulescu O. Circulation of influenza A viruses among patients hospitalized for severe acute respiratory infection in a tertiary care hospital in Romania in the 2018/19 season: results from an observational descriptive epidemiological study. Medicine 2021;100:52(e28460).

Received: 1 March 2021 / Received in final form: 8 December 2021 / Accepted: 9 December 2021

http://dx.doi.org/10.1097/MD.0000000000028460
Abstract
The seasonal circulation of influenza viruses and the impact that this infection has on the population varies from year to year. We have prospectively captured hospital-based surveillance data describing the circulation of influenza viruses and characterizing patients with influenza admitted to a tertiary hospital in Bucharest, Romania in the 2018/19 season.

We have conducted an observational descriptive epidemiological study analyzing all consecutive patients hospitalized for influenza like illness or severe acute respiratory infection at the National Institute for Infectious Diseases “Prof. Dr. Matei Baș”, Bucharest, Romania, from November 2018 to April 2019. For all patients we actively collected standardized clinical information and performed real-time reverse transcription polymerase chain reaction testing of respiratory samples to identify the presence of influenza viruses and to determine the subtype/lineage.

A total of 1128 hospitalized patients were tested in this study, with an influenza positivity rate of 41.2% (n = 465). We identified an exclusive circulation of influenza A viruses (A/H1 – 57.2%, A/H3 – 29.3%, A not subtyped – 13.3%), with only 1 case of influenza B detected at the end of the season (week 18/2019). Children under 5 years of age accounted for the majority of cases (40%, n = 186), and all cases had a favorable evolution. Females were more likely to test positive for influenza (53.3%) compared to males (46.7%), \( P = .048 \), and presence of asthma or chronic obstructive pulmonary disease increased the risk of influenza 4.4-fold and 2-fold, respectively \( (P < .001 \text{ and } P = .034) \). Thirteen influenza patients required hospitalization in intensive care and 5 deaths were recorded (1.1%). The vaccination rate for all patients included in the study was low (4.6%). The existence of chronic conditions or age over 65 years prolonged the hospitalization period with 2 days \( (P < .001 \text{ each}) \).

In the 2018/19 season, we identified an important circulation of influenza A viruses among patients hospitalized for influenza like illness/severe acute respiratory infection in a tertiary care hospital in Romania, with a higher likelihood of affecting females and patients with pre-existing lung conditions. Monitoring of the clinical and epidemiological characteristics of influenza virus infection is of great interest and should be done carefully each season to better inform on the necessary measures to limit the impact that this infection may have on risk groups.

Abbreviations: 95%CI = 95% confidence interval, COPD = chronic obstructive pulmonary disease, DRIVE = Development of Robust and Innovative Vaccine Effectiveness, GIHSN = Global Influenza Hospital Surveillance Network, ICU = intensive care unit, ILI = influenza like illness, IQR = interquartile range, LCI = laboratory-confirmed influenza, NIID = National Institute for Infectious Diseases “Prof. Dr. Matei Baș”, OR = odds ratio, RSV = respiratory syncytial virus, SARI = severe acute respiratory infection.

Keywords: clinical characteristics, hospitalization, influenza, vaccination

1. Introduction
Influenza viruses have seasonal circulation with an increased incidence during the cold season (October–May for the Northern hemisphere). In humans, they infect the respiratory epithelium, the only site where the surface viral protein, hemagglutinin, is effectively cleaved, generating infectious virus particles.\(^1\) In addition to viral infectivity, host-related factors such as age, sex, chronic conditions, genetic predisposition, and microbiome play an important role in the clinical course and outcome of the disease.\(^2\)

Although in most cases influenza is a self-limiting disease there are certain categories of patients\(^3\) – children under 5, elderly adults aged 65 and over, pregnant women and people with chronic conditions – who are at higher risk of severe complications of influenza, either bacterial superinfection or chronic disease decompensation, associating important morbidity and potentially leading to death. In these cases, influenza vaccination should be prioritized.\(^4\) Despite the fact that influenza vaccination is provided free of charge to people from risk groups in most countries including Romania,\(^5\) the overall vaccination rate remains suboptimal, well below the 75% threshold recommended for the elderly by the World Health Organization, with only 2 of the EU/EEA member states having reached this target, UK and the Netherlands, up to the 2014/15 influenza season.\(^6\)

The circulation of influenza strains has been notoriously characterized as “predictably unpredictable”. For example, in Romania, there was a completely heterogeneous circulation in the 3 seasons that preceded the one reported in this study: in 2015/16 influenza A/H1 predominated,\(^7\) in 2016/17 influenza A/H3,\(^8\) and in 2017/18 influenza B circulated in more than two-thirds of cases.\(^9,10\) For this reason, epidemiological surveillance is needed to detect temporal trends and to make informed decisions and projections regarding the upcoming influenza seasons. Under these conditions, laboratory confirmation of influenza, especially through molecular techniques, is important because it guides clinical therapeutic decisions. While surveillance data are widely available from Western European countries, less data are available for Eastern European countries, particularly Romania. Through our participation in international consortia for influenza epidemiological surveillance studies, we have prospectively captured hospital-based surveillance data.

The aim of this work is to describe the circulation of influenza viruses by type/subtype and characterize the outcomes of patients with influenza like illness (ILI)/severe acute respiratory infection (SARI) admitted to a tertiary hospital in Bucharest, Romania in the 2018/19 season.

2. Methods
2.1. Study design and study setting
In the 2018/19 influenza season, the National Institute for Infectious Diseases “Prof. Dr. Matei Baș” (NIID) was part of 2 international consortia for the surveillance of influenza: Global Influenza Hospital Surveillance Network (GIHSN)\(^5,11\) and Development of Robust and Innovative Vaccine Effectiveness (DRIVE).\(^12\) Through our participation in these consortia, we conducted a prospective study based on active surveillance of
cases of ILI or SARI, hospitalized in NIID, during the duration of the official national influenza surveillance for the season 2018/19, that is, from week 46/2018 to week 19/2019.

2.2. Study inclusion and exclusion criteria
The study methodology has been previously described in full.[5,11–13] In brief, we conducted an observational descriptive epidemiological study that included all consecutive patients who required hospitalization in NIID for 7-day onset ILI/SARI[14] and who had an admission diagnosis compatible with a clinical condition used to identify admissions possibly associated with an influenza infection, as defined by the ICD 10 codes referenced by Puig-Barberà et al.[11]

Inclusion criteria:
- Patients hospitalized for 7-day onset ILI/SARI.
- Residents in the study catchment area from Romania: Bucharest-Ilfov, Dâmboviţa, Giurgiu, Prahova, Argeş, Teleorman, Ialomiţa, Dolj, Vâlcea, Olt.
- Accepted to participate.
- Did not fulfill any of the exclusion criteria.

Exclusion criteria:
- Previously hospitalized in the 48 hours prior to symptom onset.
- Symptom onset ≥ 48 hours after admission to the hospital.
- Unwilling to participate or unable to communicate and give appropriate consent according to ethics regulations.
- Institutionalized at the time of symptoms onset.
- The respiratory specimen was taken ≥8 days after symptom onset.
- Tested positive for any influenza virus in the current season before the onset of symptoms leading to the current hospitalization.

2.3. Laboratory testing and clinical data collection
A commercial real-time reverse transcription polymerase chain reaction (RT-PCR) was used to detect the presence of influenza viruses or respiratory syncytial virus (RSV). Influenza positive samples were tested with a different rRT-PCR either to discriminate between influenza A H1 or H3 subtypes or between influenza B Yamagata or Victoria lineages, as previously described.[5] Standardized clinical and epidemiological information was collected for each patient from their medical file and through direct interview, including details on the clinical presentation at admission, presence of pre-existing comorbid diseases, influenza vaccine status, and outcome of the current hospitalization.

2.4. Ethics approval
The protocols, the informed consent forms and the standardized case report forms were approved by the Bioethics Committee of the NIID – original approvals 9378/2018 and 9379/2018. Written informed consent was obtained before performing any study procedure from all adult patients, from the parents of minor children, or from the next-of-kin in the cases where the patient’s severe clinical condition prohibited them from signing the informed consent themselves (i.e., patients receiving intensive care or mechanical ventilation at the moment of study inclusion).

2.5. Statistical analysis
The statistical analysis was performed with IBM SPSS Statistics for Windows, version 25 (IBM Corp., Armonk, NY). The level of statistical significance was set at \( P < .05 \). For continuous variables, we checked the normality of their distribution with the Shapiro-Wilk test. For variables that had normal distribution, we present the mean values and the standard deviation, and for the continuous variables with non-normal distribution we present the median and the interquartile range (IQR, defined as the 25th and 75th percentile), while the differences between the groups were analyzed with the Mann-Whitney U test and the Kruskal-Wallis H test. Effect size for the 2 tests was calculated as described in the literature.[15] For categorical variables the frequencies and percentages are reported, and we used the chi-square test to calculate the odds ratio (OR) and 95% confidence interval (95%CI).

3. Results

3.1. Laboratory results
During the study period, a total number of 1128 patients met the eligibility criteria and were tested for the presence of influenza viruses by RT-PCR (Fig. 1). The positivity rate for influenza was 41.2% (n=465), while 96 patients (8.5%) tested positive for RSV and negative for influenza.

The first case of influenza was identified in week 48/2018, and the last positive case was detected in week 18/2019. The highest rate of positivity was recorded in January and February 2019, weeks 2 to 6 (Fig. 2).

In this influenza season we identified an exclusive circulation of influenza A viruses (A/H1 – 57.2%, A/H3 – 29.3%, A not subtyped – 13.3%). Influenza A/H1 virus was identified as the main circulating subtype in all age groups (Table 1). Only 1 case of influenza B was detected, in week 18/2019, in a 45-month-old female preschooler, who had not been vaccinated against influenza, had no comorbidities, and was hospitalized for sudden onset fever, malaise, cough, and sore throat.

We detected no cases of influenza virus co-infection this season. However, 11 cases of influenza and RSV co-infection were identified – 9 cases A/H1 and 2 cases A/H3.

3.2. Characteristics and evolution of patients with laboratory-confirmed influenza
Compared with the laboratory-negative cases, there was a slight predominance of the female population among influenza-positive patients (\( P = .048 \)) (Table 2). There were no statistically significant differences in median age between influenza positive [8 years (IQR: 2, 51)] and negative [9 years (IQR: 2, 51)] patients, \( P = .753 \). Fever, headache, myalgia, cough, and general deterioration were significantly associated with laboratory-confirmed influenza (LCI) – Table 2.

A percentage of 43.0% (n=485) of the tested patients had at least 1 comorbidity. Cardiovascular disorders were the most common in both influenza-positive (16.8%) and influenza-negative (17.9%) patients. Chronic lung diseases such as chronic obstructive pulmonary disease (COPD) and asthma were associated with a 2.0, and respectively, 4.4-fold higher risk for influenza (Table 2). A percentage of 94.4% of elderly adults (≥65 years) with influenza had at least 1 associated comorbidity. Furthermore, the median (IQR) number of chronic conditions for
this age group [3(2, 4)] was significantly higher ($P < .001$) compared with the rest of the influenza patients (Table 3). Median length of hospitalization for influenza positive patients was 5 days (IQR: 3, 7) (Table 3). The existence of chronic conditions [6 days (IQR: 4, 8) for patients with chronic conditions and 4 days of hospitalization (IQR: 3, 5) for patients without chronic conditions] or age over 65 years (Table 3) prolonged the hospitalization period with 2 days ($P < .001$ each).

Among the women hospitalized for ILI/SARI, 16 were pregnant. Ten (62.5%) of them tested positive for influenza (4 cases A/H1, 4 cases A/H3, 2 cases A not subtyped), and in 1 case RSV was identified. The majority of the pregnancies were of young gestational age (mean 19.5 ± 2.78 weeks, min. 10 weeks, max. 32 weeks). In all cases, the clinical evolution was favorable. Only 31.3% ($n = 5$) of all pregnant women had been vaccinated against influenza; among these, 2 had LCI.

Among children with ages below 5 years, we identified a number of 12 patients who had been born pre-term and who were positive for influenza (Table 3). We observed that pre-term children [median (IQR) of gestational age, 34.5 (33, 36) months] displayed an 11.2-fold increased risk of admission to the intensive care unit (ICU) [$P = .002$, $\chi^2 = 9.39$, OR = 11.2, 95%CI: 1.7–

Figure 1. Patient flow chart. ILI = influenza like illness, SARI = severe acute respiratory infection.

Figure 2. Distribution of viral subtypes by calendar week during the influenza season 2018/19.
74.9] and a 5.4-fold increased risk of associating respiratory failure \[P = .013, \chi^2 = 6.23, OR = 5.4, 95\%CI: 1.3–23.0].

In case of patients with influenza-RSV co-infection, 9 (81.8\%) of the 11 patients were children under 2 years (Table 3). The median duration of hospitalization was higher, but not statistically significant among patients with co-infection [6 days (IQR: 5, 10) vs. 5 days (IQR: 3, 7), \(P = .088\)]. We also observed that patients with co-infection had a 4.4-fold higher risk of respiratory failure \[P = .012, \chi^2 = 6.3, OR = 4.4, 95\%CI: 1.25–15.60\] and a 16.6-fold higher risk of ICU admission \[P < .001, \chi^2 = 24.8, OR = 16.6, 95\%CI: 3.83–72.07\] as compared with patients who were positive only for influenza.

A total of 13 (2.8\%) patients with influenza required admission to the ICU (8 women and 5 men); 10 of them were adults with associated comorbidities, while the other 3 were children (12, 28 and 64 months, respectively) hospitalized with severe respiratory

### Table 1

Influenza positive patients by viral subtypes and age groups.

| Total patients tested, n | Influenza positive, n | Influenza subtyped, n | Influenza A/H3, n | Influenza A/H1, n | Influenza A not subtyped, n | Influenza B/Victoria, n |
|--------------------------|-----------------------|-----------------------|------------------|------------------|---------------------------|------------------------|
| Infants, <1 yr           | 91 (8.1\%)            | 48 (52.7\%)           | 29 (60.4\%)      | 17 (35.4\%)      | 2 (4.2\%)                | 0                      |
| Toddlers, 1–2 yrs        | 234 (20.7\%)          | 81 (34.6\%)           | 51 (63.0\%)      | 26 (32.1\%)      | 4 (4.9\%)                | 0                      |
| Preschoolers, 3–4 yrs    | 144 (12.8\%)          | 57 (39.6\%)           | 42 (73.7\%)      | 10 (17.5\%)      | 4 (7.0\%)                | 1 (1.8\%)              |
| School children, 5–13 yrs| 124 (11.0\%)          | 60 (48.4\%)           | 39 (65.0\%)      | 14 (23.3\%)      | 7 (11.7\%)               | 0                      |
| Teenagers, 14–17 yrs     | 16 (1.4\%)            | 4 (25.0\%)            | 2 (50.0\%)       | 0 (0.0%)         | 2 (50.0\%)               | 0                      |
| Young adults, 18–64 yrs  | 362 (32.1\%)          | 144 (39.8\%)          | 72 (50.0\%)      | 43 (29.9\%)      | 29 (20.1\%)              | 0                      |
| Elderly adults, ≥65 yrs  | 157 (13.9\%)          | 71 (45.2\%)           | 31 (43.7\%)      | 26 (36.6\%)      | 14 (19.7\%)              | 0                      |
| Total patients           | 1128 (100\%)          | 465 (41.2\%)          | 266 (57.2\%)     | 136 (29.3\%)     | 62 (13.3\%)              | 1 (0.2\%)              |

\* Percentage calculated from the total number of influenza positive.
\* No cases of influenza B/Victoria were identified.

### Table 2

Characteristics of patients tested.

| Total cases tested, n=1128/N (%) | Influenza positive, n=465/N (%) | Influenza negative, n=663/N (%) | Statistical analysis |
|----------------------------------|----------------------------------|---------------------------------|----------------------|
| Gender                           |                                  |                                 | \( P = .048, \chi^2(1) = 3.9, OR = 0.8, 95\%CI: 0.62–0.99 \) |
| Female                           | 562 (49.8\%)                     | 248 (53.3\%)                    | 314 (47.4\%)         |
| Male                             | 566 (50.2\%)                     | 217 (46.7\%)                    | 349 (52.6\%)         |
| Clinical presentations           |                                  |                                 |                      |
| Fever                            | 1069 (94.8\%)                    | 453 (47.9\%)                    | 616 (93.1\%)         |
| Malaise                          | 807 (71.5\%)                     | 341 (42.3\%)                    | 466 (70.4\%)         |
| Headache                         | 362 (32.1\%)                     | 182 (50.0\%)                    | 180 (27.2\%)         |
| Myalgia                          | 380 (33.7\%)                     | 186 (40.0\%)                    | 194 (29.3\%)         |
| Cough                            | 1012 (89.7\%)                    | 437 (43.0\%)                    | 575 (66.9\%)         |
| Sore throat                      | 392 (34.8\%)                     | 177 (38.1\%)                    | 215 (32.5\%)         |
| Shortness of breath              | 283 (25.1\%)                     | 105 (22.6\%)                    | 178 (26.9\%)         |
| Deterioration                    | 524 (46.5\%)                     | 236 (50.8\%)                    | 288 (43.5\%)         |
| Chronic conditions ≥1            | 485 (43.0\%)                     | 206 (44.3\%)                    | 279 (42.1\%)         |
| Cardiovascular disease           | 197 (17.5\%)                     | 78 (18.6\%)                     | 119 (17.9\%)         |
| COPD                             | 36 (3.2\%)                       | 21 (4.5\%)                      | 15 (2.3\%)           |
| Asthma                           | 28 (2.5\%)                       | 21 (4.5\%)                      | 7 (1.1\%)            |
| Diabetes                         | 79 (7.0\%)                       | 40 (8.0\%)                      | 39 (5.9\%)           |
| Immunodeficiency                 | 72 (6.4\%)                       | 22 (4.7\%)                      | 50 (7.5\%)           |
| Renal impairment                 | 53 (4.7\%)                       | 19 (4.1\%)                      | 34 (5.1\%)           |
| Rheumatologic disease            | 33 (2.9\%)                       | 16 (3.3\%)                      | 17 (2.6\%)           |
| Neurologic disease               | 37 (3.3\%)                       | 14 (3.4\%)                      | 30 (4.5\%)           |
| Liver disease                    | 70 (6.2\%)                       | 28 (6.0\%)                      | 42 (6.3\%)           |
| Neoplasm                         | 57 (5.1\%)                       | 21 (4.5\%)                      | 36 (5.4\%)           |
| Obesity                          | 94 (8.3\%)                       | 43 (4.3\%)                      | 51 (7.7\%)           |
| Active tuberculosis              | 4 (0.4\%)                        | 2 (0.4\%)                       | 2 (0.3\%)            |
| HIV infection                    | 30 (2.7\%)                       | 11 (2.4\%)                      | 19 (2.9\%)           |
| Influenza vaccination*, season 2018–2019 | 52 (4.6\%)                     | 20 (4.3\%)                      | 32 (4.8\%)           |
| Respiratory failure              | 137 (12.1\%)                     | 56 (12.0\%)                     | 81 (12.2\%)          |
| ICU admission                    | 35 (3.1\%)                       | 13 (2.8\%)                      | 22 (3.3\%)           |
| Mechanical ventilation           | 10 (0.9\%)                       | 4 (0.9\%)                       | 6 (0.9\%)            |
| Deaths                           | 11 (1.0\%)                       | 5 (1.1\%)                       | 6 (0.9\%)            |

\* Vaccination had occurred >14 days prior to influenza-like illness symptom onset.

95\%CI = 95 confidence interval, COPD = chronic obstructive pulmonary disease, ICU = intensive care unit, OR = odds ratio.
failure. None of the patients admitted to the ICU had been vaccinated against influenza. Of these, 4 required mechanical ventilation and 4 died, while the rest had a favorable evolution.

Among the patients confirmed with influenza there were 5 deaths (1%), all adults, 2 women and 3 men, none of them vaccinated against influenza:

- Woman, 26 years old (influenza A/H1), with hematological disease, hospitalized in the ICU and mechanically ventilated;
- Male, 37 years old (influenza A/H1) with cardiovascular disease, diabetes, renal disease, and obesity, hospitalized in the ICU and mechanically ventilated;
- Male, 40 years old (influenza A not subtyped), with HIV infection, cardiovascular disease, lung disease, neurological disease, and renal disease, hospitalized in the ICU;
- Male, 40 years old (influenza A not subtyped), with HIV infection, cardiovascular disease, lung disease, neurological disease, and obesity, hospitalized in the ICU and mechanically ventilated;
- Male, 76 years old (influenza A/H3) with cardiovascular disease, COPD, neurological disease, and obesity, hospitalized in the ICU and mechanically ventilated;
- Male, 93 years old, (influenza A/H3) with cardiovascular disease, diabetes, and renal disease, not hospitalized in the ICU.

### 3.3. Vaccination status

Overall, 4.6% (n=52) of the patients included in the study had been vaccinated against influenza in the 2018/2019 season, 48.1% of them (n=25) with quadrivalent inactivated vaccine and 51.9% (n=27) with trivalent inactivated vaccine. Of these, 53.8% (n=28) had also been vaccinated in the previous 2 influenza seasons (2016/17 and 2017/18, respectively), and 5.8% (n=3) only in the 2017/18 season. The vaccination rate was almost double in women (67.3%) as compared to men (32.7%). A number of 20 (38.5%) vaccinated patients (8 - quadrivalent vaccine and 12 - trivalent vaccine) were confirmed with influenza [9 – A/H1, 10 – A/H3, 1 – A not subtyped] (Tables 2 and 3), compared with 32 vaccinated patients (61.5%) who tested negative for influenza (P=.675). All vaccinated patients who had LCI had a favorable clinical evolution without complications.

### 4. Discussion

The current study has presented the circulation of different influenza virus types and subtypes, as well as the clinical and epidemiological characteristics of influenza in patients admitted to a tertiary hospital in Bucharest, Romania, in the 2018/19 season.

We identified an exclusive circulation of influenza A viruses (57.2% – A/H1, 29.3% – A/H3, and 13.3% – A not subtyped), and a single case of influenza B (0.2%), which is in line with the data communicated by the Romanian National Center for Surveillance and Control of Transmissible Diseases,[9] which shows that during the 2018/19 season, only 1 case of influenza B, the one reported by us, was identified in Romania. Also, the European Center for Disease Prevention and Control[16] showed that at European level, influenza A viruses have circulated in a proportion of 98.9%, with the predominance of the subtype A/H1 (57.4%), data confirming our report. This circulation is, however, different from the 2017/18 season when in Europe B-type influenza viruses circulated in a proportion of 64%.[15,17]

At the same time, the 2018/19 season was characterized by an early circulation of influenza viruses, with the first case of influenza being hospitalized in our institute in week 48/2018. An increased rate of positive influenza cases began in the weeks 2 to 3/2019, 3 weeks earlier than the 2017/18 season.[9]

It is well known that patients with chronic conditions are prone to complications of influenza and even death. In our study we identified an increased rate of comorbidities in patients with LCI (43.0%), the most frequent being cardiovascular disease. Similarly, Chung et al[18] have identified high blood pressure and coronary heart disease as the main comorbidities in patients with influenza. On the other hand, San-Roman-Montero et al.[19] in a 5-year study, have identified lung disease as the main category of comorbidities associated with influenza. In our study, we observed that patients with COPD and asthma hospitalized for ILI/SARI had a 2.0 and 4.4-fold higher risk of positivity for influenza, in line with the data seen from other studies.[20,21]

Elderly adults aged 65 and over with influenza associated a
significantly higher number of comorbidities compared to the other age groups and required longer hospitalization. Similar studies have found an increased risk of hospitalization among people ≥65 years of age with influenza, especially if they had at least 1 chronic condition.\(^1\)\(^2\) Overall, the elderly, especially those with chronic conditions or frailty, have a propensity for severe influenza outcomes. Moreover, elderly adults are vulnerable to diminished quality of life due to loss of independence following hospitalization with influenza.\(^3\)\(^4\) Therefore, public health policies must focus on protecting this group from such risks by increasing the vaccination rate and specific epidemiological measures during influenza seasons.

Pregnancy is another important risk factor for severe influenza-associated illness.\(^5\)\(^6\) In our study, we identified an influenza positive rate of 62.5% among pregnant women hospitalized for ILI. The evolution was favorable under medical supervision and treatment, in all cases. In fact, a meta-analysis of 36,498 pregnant women showed that pregnancy was associated with a 7-fold increased risk of hospitalization, but with a lower risk of admission to the ICU or death.\(^7\)\(^8\) Pregnant women represent a target group for vaccination prophylaxis, and any of the inactivated influenza vaccines can and should be safely administered in any trimester of pregnancy.\(^9\)\(^10\) In the analyzed season, in Romania, only 0.1% (approx. 1300 doses) of influenza vaccines provided free by the Ministry of Health were administered to pregnant women.\(^11\) Increasing the vaccination rate in this segment of the population is particularly important, as it has been shown to have a double benefit on both the mother and the fetus. There are studies that have shown active transplacental transfer of postvaccine antibodies and no fetal vaccine-related adverse events have been reported.\(^12\)\(^13\) Thus, passive immunity can be provided to another risk group for influenza, infants under 6 months who are too young to receive influenza vaccination.

In the case of children under 5 years, we identified pre-term birth in the patient’s history as a risk factor for admission to the ICU and the association of respiratory failure. Hardelid et al.\(^14\)\(^15\) in a study of influenza in children with ages below 2 years, identified pre-term birth (<37 weeks) as a determinant of increased risk of hospital admission.

The timely identification of co-infections with other respiratory pathogens is very important, impacting both the patient’s clinical management, and the patient’s prognosis. There are numerous studies on bacterial superinfection of influenza, in particular for Streptococcus pneumoniae, and its associated impact on the evolution of the disease.\(^16\)\(^17\)\(^18\) Viral co-infections can also be reasonably expected, given the overlap of the seasonality of the circulation of certain viruses. In our study we identified 11 (2.4%) cases of influenza-RSV co-infection. This value is comparable to another report for Romania (4.2%),\(^19\) but lower than the reports from Nepal (10.8%)\(^20\) and Madagascar (10.6%).\(^21\) Interestingly, patients with co-infection in our study exhibited an increased risk of respiratory failure and admission to the ICU compared to those with influenza without co-infection. These observations are significant and suggest the need to investigate a co-infection when hospitalizing a patient with influenza.

Influenza vaccination is available in Romania for all people over 6 months. For the 2018/19 season there were trivalent and quadrivalent inactivated influenza vaccines used in the country. The Ministry of Health provides, through general practitioners, free vaccination of people in groups at risk of developing severe influenza complications. However, the vaccination rate in the general population in Romania remains low. This aspect is observed in other countries, especially in those neighboring Romania.\(^6\)\(^19\) We reported in our study an overall low vaccination rate of 4.6%. At the national level, the Romanian National Center for Surveillance and Control of Transmissible Diseases reported a 6.8% uptake of the influenza vaccine in the general population and 20.9% in elderly patients.\(^19\) Although the percentages are low, they have somewhat increased as compared to the previous seasons: 5.2% vaccination rate for the 2017/18 season\(^19\) and 2.5% for the 2016/17 season.\(^19\) A percentage of 4.3% of the LCI cases had been vaccinated against influenza in the respective season. This rate may seem worrisome, however recent studies suggest that influenza vaccines were low to moderately effective for the 2018/19 season.\(^22\)\(^23\) This may be hypothetically due to certain mismatches between the vaccine strain and the circulating virus. However, all cases of influenza in vaccinated patients displayed a favorable evolution, without complications, suggesting that some degree of protection did indeed exist.

At national level, in Romania, the mortality rate due to influenza in the 2018/19 season was reported at 8.6%\(^19\), much higher than the one recorded in our study, where 1% of those with confirmed influenza died, all being adults with comorbidities. This reinforces the need for preventative health policies regarding the vaccination of people with chronic conditions.

Our study has aimed to provide a clear insight into the 2018/19 influenza season in Romania, an Eastern European country for which influenza surveillance data are limited. The large number of confirmed and hospitalized influenza cases, as well as the balanced breakdown by age groups of the patients included in the study provides a detailed picture of the circulation and impact of influenza in this region. The data presented are similar to other studies, but they contribute to the knowledge and characterization of seasonal variations of influenza depending on host factors, but also geographical and socio-economic factors. Our study had certain limitations: the selection of the study population was made from a single hospital, the NIID, which is also a reference center for infectious diseases in the southern region of Romania and beyond; this might have led to a large number of hospitalized influenza cases and thus a high rate of positivity among patients with ILI/SARI.

The variability of the circulation of influenza viruses from year to year underlines the necessity of continued monitoring of the impact that influenza has on the population, particularly among patients from influenza risk groups. Hence, in the long term, by comparing the data from year to year it will be possible to identify particular trends and to implement specific measures to limit the clinical impact of influenza in the population.

5. Conclusions

In this study we have reported an exclusive circulation of influenza A viruses in the 2018/19 influenza season, with the predominance of the A/H1 subtype throughout the season and in all age categories in a tertiary care hospital in Romania, with a higher likelihood of affecting females and patients with pre-existing lung conditions. In contrast to children, adults with influenza, especially those with chronic conditions and those aged 65 years and older, had more severe forms of illness that associated longer periods of hospital admission, ICU admission and, in some cases, death. Influenza surveillance remains a relevant topic, with extensive clinical and epidemiological studies
needed each season to ensure consistent monitoring of the circulation of viral strains and the clinical impact that these may have on different risk groups.

Author contributions
All authors had equal contributions.

Conceptualization: Anca Cristina Drăganescu, Victor Daniel Miron, Daniela Pitjiogoi, Adrian Streinu-Cercel, Oana Săndulescu.

Data curation: Anca Cristina Drăganescu, Victor Daniel Miron, Anca Streinu-Cercel, Daniela Pitjiogoi, Oana Săndulescu.

Formal analysis: Anca Cristina Drăganescu, Victor Daniel Miron, Anca Streinu-Cercel, Dragos Florea, Daniela Pitjiogoi, Oana Săndulescu.

Funding acquisition: Anca Cristina Drăganescu, Victor Daniel Miron, Daniela Pitjiogoi, Oana Săndulescu.

Investigation: Anca Cristina Drăganescu, Victor Daniel Miron, Anca Streinu-Cercel, Dragos Florea, Ovidiu Vlaiuc, Anuța Bilașco, Dan Oțelea, Monica Luminița Luminos, Oana Săndulescu.

Methodology: Anca Cristina Drăganescu, Victor Daniel Miron, Dragos Florea, Ovidiu Vlaiuc, Dan Oțelea, Daniela Pitjiogoi, Oana Săndulescu.

Project administration: Anca Cristina Drăganescu, Victor Daniel Miron, Oana Săndulescu.

Resources: Anca Cristina Drăganescu, Victor Daniel Miron, Dragos Florea, Ovidiu Vlaiuc, Dan Oțelea, Daniela Pitjiogoi, Oana Săndulescu.

Software: Anca Cristina Drăganescu, Victor Daniel Miron, Dragos Florea, Ovidiu Vlaiuc, Oana Săndulescu.

Supervision: Anca Cristina Drăganescu, Victor Daniel Miron, Dragos Florea, Ovidiu Vlaiuc, Dan Oțelea, Daniela Pitjiogoi, Oana Săndulescu.

Validation: Anca Cristina Drăganescu, Victor Daniel Miron, Anca Streinu-Cercel, Dragos Florea, Anuța Bilașco, Dan Oțelea, Monica Luminița Luminos, Oana Săndulescu.

Visualization: Anca Cristina Drăganescu, Victor Daniel Miron, Anca Streinu-Cercel, Dragos Florea, Oana Săndulescu.

Writing – original draft: Anca Cristina Drăganescu, Victor Daniel Miron, Oana Săndulescu.

Writing – review & editing: Anca Cristina Drăganescu, Victor Daniel Miron, Anca Streinu-Cercel, Dragos Florea, Ovidiu Vlaiuc, Anuța Bilașco, Dan Oțelea, Monica Luminița Luminos, Daniela Pitjiogoi, Adrian Streinu-Cercel, Oana Săndulescu.

References
[1] Kalil AC, Thomas PG. Influenza virus-related critical illness: pathophysiology and epidemiology. Crit Care 2019;23:258.
[2] Gounder AP, Boon AC. Influenza pathogenesis: the effect of host factors on severity of disease. J Immunol 2019;202:341–50.
[3] Grohskopf LA, Sokolow LZ, Broder KR, Walter EB, Fry AM, Jernigan DB. Prevention and control of seasonal influenza with vaccines: recommendations of the Advisory Committee on Immunization Practices-United States, 2018-19 Influenza Season. MMWR Recomm Rep 2018;67:1–20.
[4] Trombetta CM, Gianchechi E, Montomoli E. Influenza vaccines: evaluation of the safety profile. Hum Vaccin Immunother 2018;14:657–70.
[5] Drăganescu A, Săndulescu O, Florea D, et al. The influenza season 2016/17 in Bucharest, Romania - surveillance data and clinical characteristics of patients with influenza-like illness admitted to a tertiary infectious diseases hospital. Braz J Infect Dis 2018;22:377–86.
[6] European Centre for Disease Prevention and Control. Seasonal influenza vaccination in Europe. Vaccination recommendations and coverage rates in the EU Member States for eight influenza seasons 2007–2008 to 2014–2015. 2017. Available at: https://www.ecdc.europa.eu/sites/default/files/documents/influenza-vaccination-2007%e2%80%932008%e2%80%932014%e2%80%932015.pdf. Accessed October 14, 2019.
[7] Central Național de Supraveghere și Control al Bolilor Transmissibile. Analiza evoluției bolilor transmise în astăzi supraveghere - Raport pentru anul 2015. 2016. Available at: https://www.cnscbt.ro/index.php/rapoarte-aneuale/549-analiza-evolutiei-bolilor-transmise-in-supraveghere-raport-pentru-anul-2015.pdf. Accessed July 10, 2021.
[8] Central Național de Supraveghere și Control al Bolilor Transmissibile. Analiza evoluției bolilor transmise în astăzi supraveghere - Raport pentru anul 2016, 2017. Available at: https://www.cnscbt.ro/index.php/rapoarte-aneuale/779-analiza-evolutiei-bolilor-transmise-in-supraveghere-raport-pentru-anul-2016/file. Accessed July 10, 2021.
[9] Central Național de Supraveghere și Control al Bolilor Transmissibile. Analiza evoluției grpei, a infecțiilor respiratorii acute (ARI) și a infecțiilor respiratorii acute severe (SARI) în sezonul 2018-2019. 2019. Available at: https://www.cnscbt.ro/index.php/analiza-date-supraveghere/gripa-si-infec-tiile-respiratorii-acute/1208-analiza-sezon-griral-2018-2019/file. Accessed October 10, 2019.
[10] Drăganescu A, Săndulescu O, Florea D, et al. The 2017-2018 influenza season in Bucharest, Romania: epidemiology and characteristics of hospital admissions for influenza-like illness. BMC Infect Dis 2019;19:967.
[11] Puig-Barberà J, Tormos A, Trushakova S, et al. The Global Influenza Hospital Surveillance Network (GIHSN): a new platform to describe the epidemiology of severe influenza. Influenza Other Respir Viruses 2015;9:277–86.
[12] Stuurman AL, Bollaerts K, Alexandreiro M, et al. Vaccine effectiveness against laboratory-confirmed influenza in Europe - results from the DRIVE network during season 2018/19. Vaccine 2020;38:6455–63.
[13] Development of Robust and Innovative Vaccine Effectiveness (DRIVE). Core protocol for type/brand - specific influenza vaccine effectiveness studies (test-negative design studies). 2018. Available at: https://www.drive-eu.org/wp-content/uploads/2018/12/DRIVE_D7_1_Core-protocol-for-test-negative-design-studies_1_1.pdf. Accessed July 10, 2021.
[14] Săndulescu O, Drăganescu A, Pitjiogoi D. Influenza redefined - clinical and epidemiological insight. Germs 2019:9:60.
[15] Tomczak M, Tomczak E. The need to report effect size estimates revisited. An overview of some recommended measures of effect size. Trends Ecol Evol 2014;1:19–25.
[16] European Centre for Disease Prevention and Control. Influenza virus characterisation, July 2019. 2019. Available at: https://www.ecdc. europa.eu/sites/default/files/documents/influenza-virus-characterisation-report-Jul-2019.pdf. Accessed October 10, 2019.
[17] European Centre for Disease Prevention and Control. Seasonal influenza - Annual Epidemiological Report for 2017-2018. 2018. Available at: https://www.ecdc.europa.eu/sites/default/files/documents/AER_for_2017-seasonal-influenza.pdf. Accessed October 14, 2019.
[18] Chung JY, Hsu CC, Chen JH, et al. Geriatric influenza death (GID) score: a new tool for predicting mortality in older people with influenza in the emergency department. Sci Rep 2018;8:9312.
[19] San-Roman-Montero JM, Gil Prieto R, Gallardo Pino C, Hinojosa Mena J, Zapatero Gaviria A, Gil de Miguel A. Inpatient hospital mortality related to coding (ICD-9-CM) of the influenza diagnosis in Spain (2009–2015). BMC Infect Dis 2019;19:700.
[20] Vierupstandan R, Snyder JD, Samarasinghe AE. Influenza in asthmatics: for better or for worse? Front Immunol 2018;9:1843.
[21] Jha A, Dunning J, Tunstall T, et al. Patterns of systemic and local inflammation in patients with asthma hospitalised with influenza. Eur Respir J 2019;54:190049.
[22] Appiah GD, Chung JR, Flannery B, et al. Hospitalization following outpatient medical care for influenza: Us influenza vaccine effectiveness network, 2011–2012–2015–16. Influenza Other Respir Viruses 2019;13:133–7.
[23] McElhaney JE, Verschoor CP, Andrew MK, Haynes L, Kuchel GA, Pawelec G. The immune response to influenza in older humans: beyond immune senescence. J Immunity Ageing 2020;17:10.
[24] Creanga AA, Johnson TF, Graitcer SB, et al. Severity of 2009 pandemic influenza A (H1N1) virus infection in pregnant women. Obstet Gynecol 2010;115:717–26.
[25] Mertz D, Lo CK, Lytvyn L, Ortiz JR, Loeb M. FLURISK-INVESTIGATORS Pregnancy as a risk factor for severe influenza infection:
an individual participant data meta-analysis. BMC Infect Dis 2019; 19:683.

[26] Committee on Infectious Diseases. Recommendations for prevention and control of influenza in children, 2019–2020. Pediatrics 2019;144:e20192478.

[27] Simionescu AA, Streinu-Cercel A, Popescu FD, et al. Comprehensive overview of vaccination during pregnancy in Europe. J Pers Med 2021;11:1196.

[28] Vesikari T, Virta M, Heinonen S, et al. Immunogenicity and safety of a quadrivalent inactivated influenza vaccine in pregnant women: a randomized, observer-blind trial. Hum Vaccin Immunother 2020;16:623–9.

[29] Hardelid P, Verfuerden M, McNamara J, Gilbert R. Risk factors for admission to hospital with laboratory-confirmed influenza in young children: birth cohort study. Eur Respir J 2017;50:1700489.

[30] Miron VD, Drăganescu A, Vizan C, et al. Mechanisms of interaction between S. pneumoniae and influenza viruses – literature review. J Contemp Clin Pract 2017;3:8–13.

[31] Miron VD, Draganescu AC, Sandulescu O, et al. Pneumococcal colonization and pneumococcal disease in children with influenza. Rev Chim 2018;69:2749–53.

[32] Upadhyay BP, Banjara MR, Shrestha RK, Tashiro M, Ghimire P. Etiology of coinfections in children with influenza during 2015/16 winter season in Nepal. Int J Microbiol 2018;2018:8945142.

[33] Rabarison JH, Tempia S, Harimana A, et al. Burden and epidemiology of influenza- and respiratory syncytial virus-associated severe acute respiratory illness hospitalization in Madagascar, 2011–2016. Influenza Other Respir Viruses 2019;13:138–47.

[34] Bellino S, Bella A, Puzelli S, et al. Moderate influenza vaccine effectiveness against A(H1N1)pdm09 virus, and low effectiveness against A(H3N2) subtype, 2018/19 season in Italy. Expert Rev Vaccines 2019;18:1201–9.

[35] Flannery B, Kondor RJG, Chung JR, et al. Spread of antigenically drifted influenza A(H3N2) viruses and vaccine effectiveness in the United States during the 2018–2019 season. J Infect Dis 2019;221:8–15.